Korea S.E.
23:00:00 02/06/2024 BST
5-day change
1st Jan Change
14,580
KRW
+0.34%
-0.55%
-6.90%
SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd.
On December 20, 2023, SD Biotechnologies Co., Ltd closed the transaction.
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-16
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
03-14
CI
SD Biotechnologies Co., Ltd. announced that it has received KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd.
12-19
CI
SD Biotechnologies Co., Ltd. announced that it expects to receive KRW 65 billion in funding from Koino Co.Ltd., Focus Asset Management Co., Ltd., Daewon Pharmaceutical Co., Ltd.
12-14
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
SD Biotechnologies Co., Ltd. announced that it expects to receive KRW 40 billion in funding from Daewon Pharmaceutical Co., Ltd.
11-12
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
15/05/23
CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 20, 2022.
23/12/22
CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on September 20, 2022.
23/12/22
CI
Daewon Pharmaceutical Co., Ltd.'s Equity Buyback announced on September 20, 2022, has expired with 361,402 shares, representing 1.71% for CNY 6,001.69 million.
19/12/22
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
11/11/22
CI
Daewon Pharmaceutical Co., Ltd. announces an Equity Buyback for 378,549 shares.
20/09/22
CI
Daewon Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
19/09/22
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
16/08/22
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
16/05/22
CI
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
17/03/22
CI
Daewon Pharmaceutical to Launch Osteoarthritis Drug in Russia
11/02/22
MT
List Biotherapeutics, Inc. announced that it expects to receive KRW 21.342007114 billion in funding from Daewon Pharmaceutical Co., Ltd., Korea Investment & Securities Co., Ltd., Investment Arm, and other investors
29/12/21
CI
South Korean Pharmaceutical Firms Rush to Develop COVID-19 Oral Pills
29/12/21
MT
Daewon Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
15/11/21
CI
Daewon Pharmaceutical Co., Ltd. announced that it has received KRW 12 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., KB Securities Co., Ltd., Investment Arm
23/05/21
CI
Daewon Pharmaceutical Co., Ltd. announced that it expects to receive KRW 12 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd., KB Securities Co., Ltd., Investment Arm
19/05/21
CI
Daewon Pharmaceutical Co., Ltd. agreed to acquire 83.5% stake in Keukdong H-Pharm Co., Ltd. for KRW 14.1 billion.
11/05/21
CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 24, 2020.
29/06/20
CI
Tranche Update on Daewon Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 24, 2020.
29/06/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Companyâs products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.
More about the company
Last Close Price
14,580
KRW
Average target price
21,000
KRW
Spread / Average Target
+44.03%
Consensus
1st Jan change
Capi.
-6.90% 225M +42.60% 748B +32.98% 598B -5.74% 356B +17.79% 325B +3.37% 283B +16.94% 245B +8.78% 211B -4.38% 209B +6.74% 165B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
DAEWON PHARMACEUTICAL CO., LTD. 
